CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-09). The draft was written by AI, all 3 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 136 · Search date 2026-07-09 · Methodology v0.6

Acetyl-L-carnitine,
does it really help with Cognition and diabetic neuropathy?

30-Second Summary
C
Evidence Grade C · 49 · Safety caution
Evidence for neuropathy in patients should be distinguished from general cognitive-supplement claims.
What the
research shows
ALCAR has human RCT signals for diabetic neuropathy pain and some nerve markers, but the 2019 Cochrane review rated the evidence for pain reduction as very uncertain. The Cochrane review on dementia and cognition also concluded that it is unlikely to be important as a treatment for Alzheimer's disease, so the overall judgment is C.
What the
ads claim
Advertising combines phrases such as 'mitochondrial energy,' 'brain fog,' 'nerve health,' and 'diabetic foot tingling.' However, mitochondrial mechanisms are surrogate markers, and diabetic neuropathy is a medical disease area.
*

Useful facts when choosing a product

  • Neuropathy studies commonly use doses in the 1500-3000 mg/day range.
  • General cognitive-supplement doses may differ from the doses and populations in disease RCTs.
  • Gastrointestinal discomfort, insomnia, agitation, and changes in body odor may be reported.
  • Case reports of increased warfarin anticoagulant effect and caution in people with a seizure history are mentioned.
Gap Measurement · Verdict 136 · C 49
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The two RCTs in Sima 2005 Diabetes Care reported that ALCAR 500 or 1000 mg three times daily for 1 year showed signals for some pain measures and nerve-fiber regeneration markers in patients with diabetic neuropathy. However, the 2019 Cochrane review examined 4 studies with 907 participants and assessed whether pain decreased over 6-12 months as very uncertain. For dementia, the 2003 Cochrane review examined Alzheimer's disease trials but concluded that pharmacologic understanding and efficacy evidence were limited and that it was unlikely to be an important treatment.

02

Why this is classified as C (49)

There are large RCTs for diabetic neuropathy, but Cochrane certainty is low, and cognition has a negative assessment as an Alzheimer's treatment. For health-functional-food claims about cognition and nerves, directness and certainty are insufficient, so it is judged C, 49 points.

Counterpoint. Studies in patients with painful diabetic neuropathy and claims about cognitive enhancement in healthy adults are separate. This judgment addresses consumer supplement claims that bundle the two.

Rejudgment record. Draft — RCTs exist, but Cochrane certainty is low and generalization to cognition is limited.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Sima AAF et al. 20052 randomized placebo-controlled trialsPossible industry tiesPain and nerve-fiber markersReported signals for some pain measures and nerve-regeneration markers.Core
Cochrane 2019Cochrane review907Independent reviewDiabetic neuropathy painAssessed the evidence for pain reduction over 6-12 months as very uncertain.Core
Cochrane 2003Cochrane reviewIndependent reviewDementia and cognitionConcluded that ALCAR is unlikely to be an important treatment for Alzheimer's disease.Core counterexample
Li S et al. 2015/2017Meta-analysisMixedPain and electrophysiologyReported a pain-reduction signal but emphasized the need for additional RCTs.Supporting
§

Receipt — 3 References

Every cited source was opened and checked against the live page on 2026-07-09.

Sima AAF, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005.
checked
Cochrane. Acetyl-L-carnitine for treating diabetic peripheral neuropathy. 2019.
checked
Cochrane. Acetyl-L-carnitine for dementia. 2003.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none

Cite this verdict

Acetyl-L-carnitine (ALCAR) x cognition and diabetic neuropathy Evidence Grade C card
[Chamgap] Acetyl-L-carnitine (ALCAR) x cognition and diabetic neuropathy — Evidence Grade C·49. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/alcar-cognition-neuropathy/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.